Zobrazeno 1 - 10
of 530
pro vyhledávání: '"FDA Adverse Event Reporting System"'
Publikováno v:
Endocrine Connections, Vol 13, Iss 12, Pp 1-10 (2024)
Aim: Incretin therapies, including dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), are crucial for type 2 diabetes treatment. Evidence of their association with gallbladder, biliary diseases, and
Externí odkaz:
https://doaj.org/article/6d73d621ce374d4eb5999ecb8e5d8476
Autor:
Seong Kyung Kim, Myeong Gyu Kim
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract This study aimed to evaluate the association between sacubitril/valsartan and dementia-related adverse events (AEs) in geographical subpopulations using subgroup disproportionality analysis. Cases from the FDA adverse event reporting system
Externí odkaz:
https://doaj.org/article/31541ee1e2c540899c7ba7d8915116f0
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Trastuzumab emtansine (T-DM1) is widely utilized as a second-line and subsequent treatment for metastatic HER2+ breast cancer and has shown promise in early breast cancer treatment, particularly in adjuvant settings for residual disease afte
Externí odkaz:
https://doaj.org/article/cf8ea2b8612645708a91c061907a0d54
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundDrug rash with eosinophilia and systemic symptoms (DRESS) is a life-threatening severe cutaneous adverse reaction.ObjectiveThis study aims to study fatal DRESS cases using FAERS database and systematic review.MethodsData of the FDA Adverse
Externí odkaz:
https://doaj.org/article/f44d43cc7c94458db57345c6bcb73507
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionRetinal vein occlusion (RVO) often causes irreversible visual impairment, making early prevention crucial. This study aims to identify associations between different medications and RVO and provide information for clinical practice.Method
Externí odkaz:
https://doaj.org/article/e061c4e571c94c8c99d46e2c48f989c9
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundPralsetinib, a selective oral inhibitor of rearranged during transfection (RET) fusion proteins and oncogenic RET mutants, has shown significant efficacy in treating RET fusion-positive non-small cell lung cancer and thyroid cancer. However
Externí odkaz:
https://doaj.org/article/b370a1dfd9c8400b88880881b9190b94
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adve
Externí odkaz:
https://doaj.org/article/5ae4c212c0f64944b6212f9b26ad5e1c
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundAbraxane plays a crucial role in the treatment of various types of cancer, despite the considerable attention it has garnered for its adverse drug events (ADEs). Nevertheless, there is currently a significant lack of comprehensive real-worl
Externí odkaz:
https://doaj.org/article/bf3d92cde70348f183ff0f131c49423f
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundInhibitors of the anaplastic lymphoma kinase (ALK) gene mutation are first-line treatments in patients with ALK-positive lung cancer. The FDA label warns of the risk of interstitial lung disease (ILD) in patients receiving ALK TKIs. However
Externí odkaz:
https://doaj.org/article/de1bea835ce7457f820904a608365a79
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundDrug-induced lung disease (DILD) is a considerable and potentially fatal adverse event with poorly understood risk factors. Large-scale, data-driven analyses investigating regional discrepancies in DILD incidence are lacking. The aim of thi
Externí odkaz:
https://doaj.org/article/c7de1f21921d430fa548fa71b4c56341